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BACKGROUND
Generalized vitiligo is an autoimmune disease characterized by melanocyte loss, 
which results in patchy depigmentation of skin and hair, and is associated with an 
elevated risk of other autoimmune diseases.
METHODS
To identify generalized vitiligo susceptibility loci, we conducted a genomewide as-
sociation study. We genotyped 579,146 single-nucleotide polymorphisms (SNPs) in 
1514 patients with generalized vitiligo who were of European-derived white (CEU) 
ancestry and compared the genotypes with publicly available control genotypes from 
2813 CEU persons. We then tested 50 SNPs in two replication sets, one comprising 
677 independent CEU patients and 1106 CEU controls and the other comprising 183 
CEU simplex trios with generalized vitiligo and 332 CEU multiplex families.
RESULTS
We detected significant associations between generalized vitiligo and SNPs at sev-
eral loci previously associated with other autoimmune diseases. These included genes 
encoding major-histocompatibility-complex class I molecules (P = 9.05×10−23) and 
class II molecules (P = 4.50×10−34), PTPN22 (P = 1.31×10−7), LPP (P = 1.01×10−11), IL2RA 
(P = 2.78×10−9), UBASH3A (P = 1.26×10−9), and C1QTNF6 (P = 2.21×10−16). We also 
detected associations between generalized vitiligo and SNPs in two additional im-
mune-related loci, RERE (P = 7.07×10−15) and GZMB (P = 3.44×10−8), and in a locus 
containing TYR (P = 1.60×10−18), encoding tyrosinase.
CONCLUSIONS
We observed associations between generalized vitiligo and markers implicating mul-
tiple genes, some associated with other autoimmune diseases and one (TYR) that may 
mediate target-cell specificity and indicate a mutually exclusive relationship between 
susceptibility to vitiligo and susceptibility to melanoma.
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G
eneralized vitiligo is a disease in 
which patchy depigmentation of skin and 
hair results from autoimmune loss of 
melanocytes.1,2 It is a complex disorder involving 
multiple susceptibility genes and unknown envi-
ronmental triggers. Genetic linkage and candidate-
gene association studies have implicated several 
potentially contributory loci, though few have been 
consistently supported by the data.3 Patients with 
generalized vitiligo have elevated frequencies of 
other autoimmune diseases, including autoimmune 
thyroid disease, rheumatoid arthritis, psoriasis, 
adult-onset type 1 diabetes, pernicious anemia, 
systemic lupus erythematosus, and Addison’s dis-
ease,4 suggesting that these diseases involve shared 
genetic components. To identify susceptibility loci 
for generalized vitiligo, we performed a genome-
wide association study of patients with the dis-
ease who were of European-derived white (abbre-
viated as CEU) ancestry.
Me thods
Study Subjects
The initial, genomewide association study includ-
ed 1514 CEU patients from North America and the 
United Kingdom (see Table 1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). All patients met strict clini-
cal criteria for the diagnosis of generalized viti-
ligo.5 The single-nucleotide polymorphism (SNP) 
genotypes of the patients were compared with 
those of 2813 CEU controls (from data sets ob-
tained from the National Institutes of Health 
Genotype and Phenotype database [dbGaP]). We 
also carried out analyses of two independent CEU 
replication sets: replication set 1 included 677 un-
related patients with generalized vitiligo and 1106 
controls, and replication set 2 was a family-based 
cohort of 183 simplex trios and 332 multiplex 
families. We obtained written informed consent 
from all the study participants, and the study was 
approved by the institutional review board at each 
participating center. Additional protocol details 
are provided in the Supplementary Appendix.
Genotyping and Quality Control
DNA purification, genotyping, and quality-control 
procedures are described in the Supplementary 
Appendix. In the genomewide association study, 
we determined the genotypes of patients with vi-
tiligo for approximately 610,000 markers by using 
the Illumina 610-Quad BeadChip. All mitochon-
drial markers and Y-chromosome markers were 
excluded, leaving 579,146 SNPs that were present 
in both patients and controls in the genomewide 
association data set. Genotype data were then sub-
jected to extensive quality-control filtering. In the 
two replication studies, genotyping of the SNPs 
that showed genomewide significance (P<5×10−8) 
or near significance in the genomewide associa-
tion study was performed with the use of the 
Sequenom MassArray iPLEX genotyping system. 
We also imputed genotypes for rs12206499, which 
is related to major-histocompatibility-complex 
(MHC) class I molecules and for technical rea-
sons could not be genotyped, and genotyped sev-
eral SNPs in the NLRP1 (NLR family, pyrin domain–
containing 1 gene) region, which was previously 
shown to be associated with vitiligo (see the Sup-
plementary Appendix).
Statistical Analysis
After quality-control filtering of the SNPs (see the 
Supplementary Appendix), exclusion of genetic out-
liers, and exclusion of data from subjects who 
could not be matched to an appropriate control 
or patient,6 a total of 520,460 SNPs in 1392 pa-
tients and 2629 controls remained. We compared 
allele frequencies of these SNPs between the pa-
tients and controls by using the unadjusted Co-
chran–Armitage trend test7 as well as an eigen-
vector-adjusted Cochran–Armitage trend test.8 
Both yielded a genomic inflation factor of 1.048, 
indicating minimal residual population stratifica-
tion; we corrected the test statistics accordingly.9 
After quality-control filtering of data obtained 
from the replication sets, for replication set 
1 we compared the allele frequencies for the 48 
genotyped SNPs, as well as the imputed SNP 
rs12206499, in 647 patients and 1056 controls 
by using the unadjusted Cochran–Armitage trend 
test.7 In replication set 2, we tested for an as-
sociation with generalized vitiligo by using the 
family-based association test,10 version 1.5.5 (see 
the Supplementary Appendix). In the replication 
and combined analyses, P values of less than 0.05 
were considered to indicate statistical signifi-
cance (as opposed to the P<5×10−8 criterion in 
the genomewide association analysis).
R esult s
Genomewide Association Analysis
We compared the frequencies of alleles of 520,460 
autosomal and X-chromosomal SNPs in 1392 un-
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related patients with generalized vitiligo and in 
2629 controls. The quantile–quantile plot of the 
negative logarithms of genomewide P values (ex-
cluding 3411 SNPs in the MHC) largely fit the 
null distribution (predicting no significant differ-
ence in P values between the two groups) (Fig. 1), 
except at the “tail,” where the observed P values 
were smaller than those expected under the null 
hypothesis. The most significant results after all 
corrections, including correction for a genomic 
inflation factor of 1.048,9 are shown in Table 1. 
Eight chromosomal regions contained SNPs asso-
ciated with generalized vitiligo at the genomewide 
significance level (P<5×10−8).11 Summary statisti-
cal results and genotype data can be obtained from 
dbGaP (accession number, phs000224.v1.p1).
MHC Loci
The most strongly associated SNPs were distrib-
uted across the MHC on chromosome 6p21.3 (Fig. 
1), with 124 MHC SNPs exceeding the threshold 
for genomewide significance (P<5×10−8) and 689 
MHC SNPs ranked among the 2000 SNPs with the 
highest genomewide significance. We found two 
major MHC association peaks (Fig. 2). One peak 
was in the class I gene region, between HLA-A (en-
coding the MHC class I,HLA-A molecule) and HCG9 
(encoding the HLA complex group 9), character-
ized by three SNPs: rs12206499 (P = 1.24×10−19 for 
the association with generalized vitiligo; odds ra-
tio for the presence of the risk allele in patients vs. 
controls, 1.58), rs3823355 (P = 2.13×10−19; odds ra-
tio, 1.57), and rs6904029 (P = 7.89×10−19; odds ra-
tio, 1.56). The second peak was in the class II gene 
region, between HLA-DRB1 (the MHC class II, DR 
beta 1 gene) and HLA-DQA1 (the MHC class II, DQ 
alpha 1 gene), characterized by rs532098 (P = 4.83× 
10−30; odds ratio, 1.74) and rs3806156 (P = 4.97× 
10−18; odds ratio, 1.53). The highest odds ratio in 
the genomewide association study was 2.48, for 
rs7758128 (P = 7.21×10−15). A third, lower peak was 
located at the proximal end of the MHC class I 
gene region (Fig. 2A).
SNPs in the two major association peaks, one 
in the MHC class I region and one in the MHC 
class II region, corresponded with different link-
age-disequilibrium blocks (Fig. 2, and Table 2 
in the Supplementary Appendix). To determine 
whether these two peaks represent independent 
associations with generalized vitiligo, rather than 
secondary associations due to long-range linkage 
disequilibrium across the MHC, we applied logis-
tic-regression analysis12 to the 22 MHC-region 
SNPs that showed the strongest association with 
generalized vitiligo in the genomewide associa-
tion study (Table 3 in the Supplementary Appen-
dix). We observed that the major peak in the MHC 
class I region, represented by SNP rs12206499, 
and the major peak in the MHC class II region, 
represented by rs532098, constitute independent 
association signals, with no apparent epistasis be-
tween them (P = 0.38), indicating that susceptibil-
ity to vitiligo that is attributable to the MHC in-
volves more than one locus.
We analyzed data for 180 participants from 27 
CEU Centre d’Etude du Polymorphisme Humain 
(CEPH) reference families for whom class I and 
class II HLA genotypes, as well as SNP geno-
types,13,14 were available and for 203 participants 
from 78 families with generalized vitiligo for 
whom class II HLA and SNP genotypes were 
available.15 We found strong linkage disequilib-
rium between the risk allele (G) at rs12206499 
and HLA-A*02 (r2 = 0.964 and linkage-disequilib-
rium coefficient [D′] = 1.0 in the CEPH reference 
families) and moderate linkage disequilibrium be-
tween the risk allele (T) at rs532098 and HLA-
DRB1*04 (r2 = 0.43 and D′ = 1.0 in the CEPH 
reference families; r2 = 0.19 and D′ = 0.83 in the 
families with generalized vitiligo). These findings 
were consistent with previous reports of an as-
sociation of generalized vitiligo with both the 
HLA-A*02 allele16 and the HLA-DRB1*04 allele.15
Non-MHC Loci
Outside the MHC region, SNPs in seven different 
chromosomal regions showed a significant as-
sociation with generalized vitiligo (Table 1 and 
Fig. 1 in the Supplementary Appendix). Five of 
these regions contain genes previously shown to 
be associated with other autoimmune diseases; 
for each region, the same high-risk SNP alleles 
associated with vitiligo were also associated with 
other autoimmune diseases.
We found an association between generalized 
vitiligo and SNP rs2476601 (P = 9.82×10−9; odds 
ratio for the presence of the risk allele in pa-
tients vs. controls, 1.54), on chromosome 1p13.2. 
This SNP is located in PTPN22, which encodes the 
lymphoid-specific protein tyrosine phosphatase, 
nonreceptor type 22, involved in T-cell–receptor 
signaling. The implicated variant is associated 
with many autoimmune diseases, including gen-
eralized vitiligo, and specifies an amino acid sub-
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Figure 1. Genomewide Association Results.
The genomewide distribution of −log10 P values from the unadjusted Cochran–Armitage trend test is shown across the chromosomes. 
Values are shown for 520,460 polymorphic SNPs that were of sufficient quality, after quality-control filtering, in 1392 unrelated CEU pa-
tients with generalized vitiligo and 2629 unrelated CEU controls, after genetic matching6 and correction for the inflation factor of 1.048. 
The dotted line indicates the genomewide significance threshold (P<5×10−8). The inset shows quantile–quantile plots of the observed 
versus expected –log10 P values from the unadjusted Cochran–Armitage trend test. The plot in red shows P values for all 520,460 SNPs, 
whereas the plot in blue shows P values for all 520,460 SNPs excluding the 3417 SNPs located across the extended major histocompati-
bility complex (MHC) (on chromosome 6, spanning 26.0 to 33.5 Mb). C1QTNF6 denotes the C1q and tumor necrosis factor–related pro-
tein 6 gene, HLA-A the MHC class I,HLA-A gene, HLA-DRB1 the MHC class II, DR beta 1 gene, IL2RA the interleukin-2–receptor alpha 
gene, LPP the LIM domain–containing preferred translocation partner in lipoma gene, PTPN22 the lymphoid-specific protein tyrosine 
phosphatase, nonreceptor type 22 gene, RERE the arginine–glutamic acid dipeptide (RE) repeats gene, TYR the tyrosinase gene, and 
UBASH3A the ubiquitin-associated and SH3 domain–containing A gene.
stitution, R620W, thought to have a direct effect 
on autoimmune susceptibility (rather than a be-
nign effect through linkage disequilibrium with 
the “causal” SNP).17
We also found an association between gener-
alized vitiligo and 11 SNPs on chromosome 3q28. 
These SNPs span the LPP gene region (including 
the LPP gene, encoding the LIM domain–contain-
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ing preferred translocation partner in lipoma). 
Of the 11 SNPs, rs1464510 (P = 6.45×10−9; odds 
ratio, 1.32) and rs13076312 (P = 3.96×10−8; odds 
ratio, 1.30) showed genomewide significance. We 
observed tight linkage disequilibrium among most 
of the 11 SNPs; no haplotype was more strongly 
associated with disease than any component SNP. 
SNPs in the LPP gene region have also been associ-
Table 1. Loci Most Strongly Associated with Generalized Vitiligo, According to the Analysis.*
Locus Region† SNP
Nucleotide 
Location
Risk 
Allele Genomewide Association Study‡
Risk-Allele Frequency
EIGENSTRAT 
P Value
PLINK 
P Value
Odds Ratio 
(95% CI)
Patients Controls
Chromosome 1p36.23
RERE rs301819 8424373 A 0.485 0.417 1.65×10−8 8.85×10−9 1.32 (1.21–1.45)
RERE rs4908760 8448729 G 0.433 0.373 6.52×10−7 3.48×10−7 1.28 (1.17–1.41)
RERE rs11121194 8492493 C 0.435 0.375 9.35×10−6 3.00×10−7 1.28 (1.17–1.41)
Chromosome 1p13.2
PTPN22 rs2476601 114179091 A 0.134 0.095 6.79×10−9 9.82×10−9 1.54 (1.33–1.78)
Chromosome 3q28
LPP rs13076312 189571948 T 0.510 0.445 3.46×10−8 3.96×10−8 1.30 (1.19–1.43)
LPP rs1464510 189595248 T 0.508 0.439 5.91×10−9 6.45×10−9 1.32 (1.21–1.45)
LPP rs13091753 189597283 T 0.459 0.399 7.36×10−7 7.83×10−7 1.27 (1.16–1.39)
LPP rs1559810 189607048 T 0.458 0.398 6.52×10−7 7.37×10−7 1.27 (1.16–1.39)
Chromosome 6p21.3**
HLA-G rs2975033 29930240 T 0.382 0.289 9.12×10−16 1.16×10−15 1.49 (1.36–1.64)
HLA-A rs2517715 30025418 G 0.423 0.336 1.47×10−12 1.66×10−12 1.41 (1.29–1.55)
HLA-A–HCG9 rs3903160 30040876 T 0.382 0.285 8.75×10−17 1.04×10−16 1.52 (1.38–1.67)
HLA-A–HCG9 rs6457110 30041860 A 0.487 0.397 9.51×10−13 9.36×10−13 1.41 (1.29–1.55)
HLA-A–HCG9 rs3893464 30043229 C 0.625 0.535 1.72×10−12 1.44×10−12 1.38 (1.20–1.59)
HLA-A–HCG9 rs12206499 30045106 G 0.395 0.288 6.15×10−20 1.24×10−19 1.58 (1.43–1.74)
HLA-A–HCG9 rs3823355 30050062 T 0.392 0.286 1.12×10−19 2.13×10−19 1.57 (1.43–1.73)
HCG9 rs6904029 30051046 A 0.391 0.287 4.06×10−19 7.89×10−19 1.56 (1.42–1.72)
HCG9 rs3823375 30052137 C 0.418 0.324 1.48×10−15 2.15×10−15 1.48 (1.35–1.63)
HCG9–HLA-J rs4947244 30062343 G 0.367 0.273 5.34×10−16 7.62×10−16 1.51 (1.37–1.66)
HLA-J rs4959039 30065048 G 0.366 0.273 8.82×10−16 1.28×10−15 1.50 (1.36–1.66)
HLA-J rs9357092 30092231 A 0.369 0.273 1.28×10−16 1.72×10−16 1.52 (1.38–1.68)
ZNRD1 rs9366752 30132656 T 0.307 0.228 6.17×10−13 6.59×10−13 1.47 (1.33–1.63)
RNF39 rs4711209 30155382 A 0.368 0.272 1.67×10−16 2.28×10−16 1.52 (1.38–1.67)
RNF39–TRIM31 rs6909253 30163622 G 0.508 0.414 2.51×10−13 1.70×10−13 1.42 (1.30–1.56)
RNF39–TRIM31 rs9261394 30172541 A 0.512 0.417 1.26×10−13 6.99×10−14 1.43 (1.31–1.57)
C6orf10–BTNL2 rs7758128 32453261 A 0.062 0.026 3.85×10−15 7.21×10−15 2.48 (1.97–3.12)
BTNL2–HLA-DRA rs3806156 32481676 T 0.474 0.370 2.31×10−18 4.97×10−18 1.53 (1.39–1.68)
HLA-DRA–HLA-DRB5 rs2395185 32541145 T 0.414 0.331 6.74×10−13 1.04×10−12 1.42 (1.29–1.56)
HLA-DRB1–HLA-DQA1 rs2516049 32678378 G 0.410 0.319 7.04×10−15 1.07×10−14 1.47 (1.33–1.61)
HLA-DRB1–HLA-DQA1 rs532098 32686030 T 0.597 0.458 2.89×10−30 4.83×10−30 1.74 (1.59–1.92)
HLA-DQA1 rs34518860 32702081 A 0.170 0.107 2.07×10−15 2.10×10−15 1.72 (1.51–1.96)
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Replication Set 1§ Replication Set 2¶ Combined Analysis‖
P Value
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI)
Pseudo 
R2
5.37×10−7 1.42 (1.24–1.63) 0.06 1.17 (0.96–1.43) 4.88×10−9 1.32 (1.20–1.45)
1.02×10−8 1.50 (1.30–1.72) 0.27 1.09 (0.89–1.33) 7.07×10−15 1.36 (1.26–1.48) 0.008
4.76×10−8 1.47 (1.28–1.69) 0.26 1.09 (0.89–1.33) 1.33×10−14 1.36 (1.26–1.47)
0.59 1.07 (0.84–1.69) 2.18×10−3 1.45 (1.04–2.03) 1.31×10−7 1.39 (1.23–1.57) 0.004
8.52×10−5 1.33 (1.15–1.53) 2.31×10−3 1.23 (1.01–1.50) 2.70×10−11 1.30 (1.20–1.41)
2.39×10−4 1.31 (1.13–1.51) 1.99×10−3 1.26 (1.03–1.54) 1.01×10−11 1.31 (1.21–1.41) 0.007
4.47×10−3 1.24 (1.07–1.41) 0.03 1.19 (0.98–1.46) 1.03×10−8 1.26 (1.16–1.36)
3.87×10−3 1.24 (1.07–1.43) 0.03 1.17 (0.96–1.43) 9.90×10−9 1.26 (1.16–1.36)
7.90×10−4 1.29 (1.11–1.49) 1.20×10−5 1.54 (1.23–1.92) 3.72×10−19 1.45 (1.34–1.57)
5.35×10−4 1.29 (1.11–1.48) 6.68×10−4 1.36 (1.10–1.68) 3.64×10−16 1.39 (1.28–1.51)
1.43×10−3 1.28 (1.10–1.48) 2.40×10−5 1.49 (1.19–1.85) 3.40×10−19 1.45 (1.34–1.57)
5.48×10−5 1.34 (1.16–1.54) 3.27×10−4 1.39 (1.11–1.73) 5.25×10−18 1.41 (1.30–1.52)
4.55×10−6 1.38 (1.20–1.59) 8.05×10−4 1.44 (1.44–1.81) 3.54×10−18 1.42 (1.31–1.54)
1.47×10−5 1.34 (1.17–1.53) ND 0.014
8.69×10−4 1.29 (1.11–1.50) 2.50×10−6 1.52 (1.21–1.91) 9.05×10−23 1.50 (1.39–1.63)
1.50×10−3 1.27 (1.10–1.47) 2.40×10−5 1.49 (1.18–1.87) 9.79×10−22 1.49 (1.37–1.61)
3.72×10−3 1.24 (1.07–1.43) 1.73×10−4 1.39 (1.13–1.72) 1.26×10−17 1.42 (1.31–1.53)
6.86×10−3 1.23 (1.06–1.43) 6.45×10−5 1.49 (1.19–1.86) 1.96×10−17 1.43 (1.32–1.55)
3.25×10−3 1.25 (1.08–1.46) 1.00×10−5 1.58 (1.26–1.97) 2.23×10−17 1.43 (1.32–1.55)
3.92×10−3 1.25 (1.07–1.45) 3.20×10−5 1.53 (1.22–1.91) 3.14×10−18 1.44 (1.33–1.57)
1.35×10−3 1.29 (1.10–1.51) 2.19×10−4 1.45 (1.15–1.83) 1.56×10−15 1.42 (1.30–1.55)
4.53×10−3 1.24 (1.07–1.44) 9.20×10−5 1.47 (1.18–1.84) 5.29×10−18 1.44 (1.32–1.56)
5.94×10−4 1.28 (1.11–1.50) 4.13×10−4 1.44 (1.17–1.78) 2.13×10−15 1.37 (1.27–1.48)
1.05×10−3 1.27 (1.10–1.46) 8.76×10−4 1.41 (1.14–1.75) 2.20×10−15 1.37 (1.27–1.48)
1.50×10−3 1.79 (1.24–2.56) 5.00×10−7 3.66 (2.22–6.04) 3.29×10−16 2.19 (1.80–2.65)
0.01 1.20 (1.04–1.38) 5.00×10−7 1.72 (1.38–2.13) 7.22×10−19 1.42 (1.32–1.54)
0.10 1.13 (0.97–1.32) 1.13×10−3 1.33 (1.06–1.66) 2.11×10−13 1.35 (1.25–1.47)
0.02 1.19 (1.03–1.39) 4.71×10−4 1.40 (1.12–1.75) 3.24×10−16 1.40 (1.29–1.52)
3.95×10−4 1.28 (1.11–1.46) 6.00×10−9 1.87 (1.49–2.36) 4.50×10−34 1.62 (1.50–1.75) 0.018
ND ND
ated with celiac disease and rheumatoid arthritis18; 
the function of the LPP protein is unknown.
Generalized vitiligo was also associated with 
25 SNPs in the region of IL2RA (encoding the in-
terleukin-2–receptor alpha chain) on chromosome 
10p15.1, 8 of which showed genomewide signifi-
cance. Of these, rs706779 (P = 1.14×10−9; odds 
ratio, 1.35) and rs7090530 (P = 1.54×10−9; odds 
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Table 1. (Continued.)
Locus Region† SNP
Nucleotide 
Location
Risk 
Allele Genomewide Association Study‡
Risk-Allele Frequency
EIGENSTRAT 
P Value
PLINK 
P Value
Odds Ratio 
(95% CI)
Patients Controls
Chromosome 10p15.1
IL2RA rs706779 6138830 A 0.607 0.535 4.61×10−10 1.14×10−9 1.35 (1.23–1.48)
IL2RA rs7090530 6150881 A 0.669 0.599 1.07×10−9 1.54×10−9 1.35 (1.23–1.49)
IL2RA–RBM17 rs12251307 6163501 C 0.913 0.871 1.40×10−8 1.10×10−8 1.59 (1.36–1.86)
RBM17 rs4750005 6209691 T 0.587 0.520 6.97×10−9 1.12×10−8 1.32 (1.20–1.45)
RBM17–PFKB3 rs3920615 6216786 A 0.615 0.544 1.11×10−9 2.11×10−9 1.34 (1.22–1.47)
RBM17–PFKB3 rs4747887 6217688 T 0.615 0.544 1.21×10−9 2.34×10−9 1.34 (1.22–1.47)
RBM17–PFKB3 rs4750012 6217800 C 0.615 0.544 1.27×10−9 2.42×10−9 1.34 (1.22–1.47)
RBM17–PFKB3 rs7099083 6218242 G 0.615 0.544 1.21×10−9 2.27×10−9 1.34 (1.22–1.47)
Chromosome 11q14.3
TYR rs10830236 88540464 C 0.721 0.669 1.09×10−6 1.15×10−6 1.29 (1.17–1.43)
TYR rs11018528 88570025 A 0.764 0.707 3.69×10−8 3.25×10−8 1.36 (1.22–1.51)
TYR rs10765198 88609422 T 0.771 0.715 5.36×10−8 5.78×10−8 1.36 (1.22–1.51)
TYR rs1847134 88644901 A 0.754 0.685 2.37×10−10 2.01×10−10 1.42 (1.28–1.57)
TYR rs1393350 88650694 G 0.807 0.733 3.70×10−13 3.24×10−13 1.54 (1.37–1.72)
TYR rs1806319 88677584 A 0.692 0.630 7.86×10−8 8.52×10−8 1.31 (1.19–1.45)
Chromosome 14q12
GZMB rs8192917 24172000 G 0.282 0.236 3.46×10−6 5.54×10−6 1.28 (1.15–1.42)
GZMB rs2273844 24173254 A 0.280 0.236 5.74×10−6 9.24×10−6 1.28 (1.15–1.42)
Chromosome 21q22.3
UBASH3A rs11203203 42709255 A 0.432 0.373 1.56×10−7 1.72×10−7 1.30 (1.18–1.42)
UBASH3A rs2839511 42721590 A 0.287 0.227 9.71×10−9 1.17×10−8 1.36 (1.23–1.51)
Chromosome 22q13.1
C1QTNF6 rs229527 35911431 T 0.490 0.419 4.06×10−9 4.36×10−9 1.33 (1.21–1.46)
C1QTNF6 rs5756546 35919751 T 0.271 0.219 6.35×10−7 4.34×10−7 1.33 (1.19–1.48)
* Odds ratios are for the presence of the risk allele among patients with generalized vitiligo as compared with controls. CI denotes confi-
dence interval, and SNP single-nucleotide polymorphism.
† Genes in close proximity to the designated SNP are listed.
‡ The genomewide association study included data for 1392 patients and 2629 controls, after quality-control filtering was performed (see 
the Supplementary Appendix, available with the full text of this article at NEJM.org). P values were calculated with the use of either the 
EIGENSTRAT (eigenvector-adjusted)8 or PLINK (unadjusted)7 Cochran–Armitage trend test statistics, which were calculated after genetic 
matching6 correction of the data set and were adjusted for the genomic inflation factor of 1.048 by means of the genomic control meth-
od.9 Odds ratios were calculated from the coefficients of the logistic-regression equations.
§ Replication set 1 consisted of data for 647 patients and 1056 controls, after quality-control filtering was performed (see the Supplementary 
Appendix). P values were calculated with the use of the Cochran–Armitage trend test. Odds ratios were calculated from the coefficients of 
the logistic-regression equations.
¶ Replication set 2 consisted of 183 trios and 332 multiplex families. P values were calculated with the use of the family-based association 
test,10 version 1.5.5. Odds ratios were calculated by means of conditional logistic-regression analysis.12
‖ The combined analysis included data from the genomewide association study and both replication sets. P values and odds ratios were cal-
culated with the use of the Cochran–Mantel–Haenszel test. The pseudo R2 values, which are measures of the total risk of the disease ac-
counted for by the given genetic variant, are given for individual independent association signals, calculated from the logistic-regression 
model.
** For chromosome 6p21.3, an additional 102 SNPs in the MHC region met the P<5×10−8 criterion for significance in the genomewide asso-
ciation study. SNPs rs12206499 and rs34518860 could not be genotyped in the replication sets, for technical reasons; thus, some data in 
the table are indicated as not done (ND). Genotypes for rs12206499 were imputed in replication set 1, on the basis of patterns of haplo-
type variation in the HapMap CEU samples (see the Supplementary Appendix). Genotypes for rs34518860 could not be imputed. SNP po-
sitions are taken from build 36.1 of the National Center for Biotechnology Information.
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Replication Set 1§ Replication Set 2¶ Combined Analysis||
P Value
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI) P Value
Odds Ratio 
(95% CI)
Pseudo 
R2
0.27 1.08 (0.94–1.24) 8.30×10−5 1.32 (1.07–1.62) 2.78×10−9 1.27 (1.17–1.37) 0.004
0.51 1.05 (0.91–1.21) 4.40×10−5 1.29 (1.05–1.58) 1.21×10−8 1.26 (1.17–1.37)
0.22 0.87 (0.70–1.09) 0.06 1.19 (0.85–1.66) 8.10×10−6 1.33 (1.18–1.52)
0.38 1.09 (0.90–1.30) 6.97×10−3 1.27 (0.97–1.66) 1.35×10−8 1.27 (1.17–1.37)
0.71 1.03 (0.89–1.18) 0.17 1.06 (0.84–1.34) 9.32×10−9 1.26 (1.16–1.36)
0.60 1.04 (0.90–1.20) 0.20 1.04 (0.83–1.31) 6.83×10−9 1.26 (1.17–1.36)
0.70 1.03 (0.89–1.19) 0.29 1.01 (0.80–1.26) 9.25×10−9 1.26 (1.16–1.36)
0.65 1.03 (0.90–1.19) 0.23 1.03 (0.82–1.29) 7.20×10−9 1.26 (1.17–1.36)
6.05×10−3 1.25 (1.07–1.46) 0.77 1.04 (0.83–1.31) 1.18×10−8 1.28 (1.18–1.40)
4.00×10−3 1.27 (1.08–1.50) 0.48 1.01 (0.81–1.26) 1.69×10−10 1.34 (1.23–1.47)
1.23×10−3 1.31 (1.11–1.55) 0.36 1.04 (0.84–1.29) 6.37×10−11 1.35 (1.23–1.48)
1.95×10−5 1.42 (1.21–1.66) 0.40 1.03 (0.82–1.30) 3.76×10−15 1.42 (1.30–1.56)
4.37×10−6 1.51 (1.26–1.79) 0.12 1.16 (0.91–1.47) 1.60×10−18 1.53 (1.39–1.68) 0.011
1.47×10−4 1.34 (1.15–1.56) 0.83 1.04 (0.83–1.30) 2.12×10−11 1.33 (1.22–1.44)
4.87×10−4 1.33 (1.13–1.55) 0.03 1.35 (1.09–1.67) 3.44×10−8 1.28 (1.17–1.39) 0.005
4.04×10−4 1.33 (1.14–1.56) 0.02 1.40 (1.13–1.75) 6.78×10−8 1.27 (1.17–1.39)
2.58×10−3 1.24 (1.08–1.43) 0.04 1.15 (0.93–1.43) 1.26×10−9 1.27 (1.18–1.38) 0.005
0.13 1.13 (0.96–1.32) 0.02 1.21 (0.95–1.53) 5.14×10−9 1.30 (1.19–1.42)
6.26×10−9 1.54 (1.33–1.78) 2.88×10−3 1.15 (0.94–1.40) 2.21×10−16 1.38 (1.28–1.50) 0.009
1.37×10−5 1.44 (1.22–1.70) 0.49 1.12 (0.91–1.40) 1.93×10−11 1.35 (1.24–1.48)
ratio, 1.35) had the strongest association. Vari-
ants of IL2RA have been shown to be associated 
with type 1 diabetes,19 Graves’ disease,20 multiple 
sclerosis,21 rheumatoid arthritis,22 and systemic 
lupus erythematosus.23 Elevated serum interleu-
kin-2–receptor levels, which indicate T-cell activa-
tion,24 occur in many autoimmune diseases, in-
cluding generalized vitiligo.25
There was also an association between gener-
alized vitiligo and nine SNPs in the region span-
ning UBASH3A (the ubiquitin-associated and SH3 
domain–containing A gene) on chromosome 
21q22.3; of these, rs2839511 showed genomewide 
significance (P = 1.17×10−8; odds ratio, 1.36). 
UBASH3A encodes a regulator of T-cell–receptor 
signaling and is associated with type 1 diabetes.26 
Also associated with type 1 diabetes27.28 (as well 
as rheumatoid arthritis29) are variants of C1QTNF6 
(the C1q and tumor necrosis factor–related pro-
tein 6 gene), located on chromosome 22q13.1. The 
SNP rs229527 at this locus showed an associa-
tion with generalized vitiligo (P = 4.36×10−9; odds 
ratio, 1.33).
In addition, we observed an association be-
tween generalized vitiligo and two non-MHC re-
gions that have not previously been reported to be 
associated with autoimmune disease. The first was 
the RERE gene region (encoding the arginine–
glutamic acid dipeptide [RE] repeats protein, also 
known as atrophin-like protein 1) on chromosome 
1p36.23, in which 40 SNPs were identified as hav-
ing an association, 1 of which showed genome-
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wide significance (rs301819; P = 8.85×10−9; odds 
ratio, 1.32). The most strongly associated SNPs in 
the RERE region were in tight linkage disequilib-
rium; no haplotype showed a significantly stron-
ger association than any component SNP. The 
RERE protein is a transcriptional corepressor30 
that is highly expressed in lymphoid cells and is 
thought to regulate apoptosis.31
Perhaps the most interesting association that 
we found was between generalized vitiligo and a 
locus on chromosome 11q14.3, consisting of 37 
SNPs spanning the TYR gene region. The major 
allele of each SNP was associated with vitiligo. 
Three of these SNPs showed genomewide sig-
nificance; the strongest associations were with 
rs1847134 (P = 2.01×10−10; odds ratio, 1.42) and 
rs1393350 (P = 3.24×10−13; odds ratio, 1.54). Hap-
lotype analysis revealed a strong association with 
a block of six SNPs in tight linkage disequili b-
rium — rs1018528, rs10765198, rs1847134, 
rs1393350, rs1126809, and rs1806319 — although 
no haplotype had a significantly stronger associa-
tion with generalized vitiligo than any component 
SNP. TYR encodes tyrosinase, a melanosomal en-
zyme that catalyzes the rate-limiting steps of 
melanin biosynthesis32 and constitutes a major 
autoantigen in generalized vitiligo.1,2
Finally, we detected a suggestive association 
signal at chromosome 14q12, involving 11 SNPs 
spanning the GZMB (the granzyme B gene) region, 
particularly intragenic SNPs rs8192917 (P = 5.54× 
10−6; odds ratio, 1.28) and rs2273844 (P = 9.24× 
10−6; odds ratio, 1.28). Granzyme B is a caspase-
like serine protease that mediates two processes: 
immune-induced target-cell apoptosis mediated by 
cytotoxic T cells and natural killer cells33 and acti-
vation-induced cell death of effector type 2 helper 
T cells, which terminates the immune response.34
Independent Replication and Combined 
Analyses
We aimed to replicate the results of the genome-
wide association analysis in two replication sets 
of independently collected samples from CEU pa-
tients and controls (replication set 1) and CEU 
simplex trios and multiplex families (replication 
set 2) (Table 1 in the Supplementary Appendix). 
Specifically, we tested 50 SNPs in nine chromo-
somal regions that had the strongest associations 
with generalized vitiligo, as detected in the genome-
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Figure 2. Detailed Results from the Genomewide Association Study  
and the Linkage-Disequilibrium Plot across the Major Histocompatibility 
Complex (MHC) on Chromosome 6p21.3.
Panel A shows the distribution of −log10 P values from the unadjusted  
Cochran–Armitage trend test in the genomewide association analysis, cor-
rected by the genomic inflation factor of 1.048, for the 3417 SNPs located 
across the extended MHC region (on chromosome 6, spanning 26.0 to  
33.5 Mb). Panel B shows the plot of linkage disequilibrium (r 2) for the 22 
SNPs in the MHC region that were highly associated with generalized vitili-
go and that were included in the logistic-regression analysis. The plot gives 
the physical positions of the markers (according to build 36.1 from the Na-
tional Center for Biotechnology Information). Darker boxes indicate stron-
ger linkage disequilibrium (range of possible r 2 values, 0.0 to 1.0). BTNL2 
denotes the butyrophilin-like protein 2 gene, HCG9 the HLA complex group 
9 gene, HLA-A the MHC class I, HLA-A gene, HLA-DQA1 the MHC class II, 
DQ alpha 1 gene, and HLA-DRB1 the MHC class II, DR beta 1 gene.
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wide association analysis (Table 1). In one or 
both replication sets, the results for most of these 
SNPs, and all the corresponding genomic regions 
tested, replicated the associations observed in the 
genomewide association analysis. Furthermore, 
a combined meta-analysis of all three study sets 
(by means of a Cochran–Mantel–Haenszel test) 
provided strong evidence of an association of all 
of these loci with generalized vitiligo (Table 1).
In the MHC region, both replication analyses 
and the combined analyses supported strong 
association in both the distal class I region 
(rs3823355; in the combined analysis, P = 9.05× 
10−23; odds ratio, 1.50) and the HLA-DRB1–DQA1 
class II region (rs532098; in the combined analy-
sis, P = 4.50×10−34; odds ratio, 1.62). SNPs in the 
proximal class I region were not tested in the 
replication studies.
Outside the MHC, associations in the LPP re-
gion of chromosome 3q28, the GZMB region of 
chromosome 14q12, the UBASH3A region of chro-
mosome 21q22.3, and the C1QTNF6 region of 
chromosome 22q13.1 were observed in both rep-
lication sets; the combined analysis likewise pro-
vided strong support for the associations (for LPP 
rs1464510, P = 1.01×10−11; odds ratio, 1.31; for 
GZMB rs8192917, P = 3.44×10−8; odds ratio, 1.28; 
for UBASH3A rs11203203, P = 1.26×10−9; odds ratio 
1.27; and for C1QTNF6 rs229527, P = 2.21×10−16; 
odds ratio, 1.38). For PTPN22 on chromosome 
1p13.2 and the IL2RA region of chromosome 
10p15.1, associations were replicated in the fam-
ily-based set (replication set 2) but not in the 
case–control set (replication set 1). Conversely, in 
the RERE region of chromosome 1p36.23 and the 
TYR region of chromosome 11q14.3, associations 
were replicated in the case–control set but not in 
the family-based set (Table 1). Nevertheless, for 
all these loci, the combined analysis provided 
strong support for an overall association (RERE 
rs4908760, P = 7.07×10−15; odds ratio, 1.36; PTPN22 
rs2476601, P = 1.31×10−7; odds ratio, 1.39; IL2RA 
rs706779, P = 2.78×10−9; odds ratio, 1.27; and TYR 
rs1393350, P = 1.60×10−18; odds ratio, 1.53).
Thus, the replication studies showed consistent 
support for an association of generalized vitiligo 
with SNPs within or near LPP, the HLA class I 
and HLA class II genes, GZMB, UBASH3A, and 
C1QTNF6 and less consistent, although significant, 
support for an association with SNPs within or 
near RERE, PTPN22, IL2RA, and TYR. 
Tyrosinase is naturally presented by HLA-
A*0201 and is recognized by autologous cyto-
toxic T lymphocytes on HLA-A2–positive mela-
nomas, which tend to show good response to 
immunotherapy. Presentation of TYR peptide by 
HLA-A*0201 may also mediate the loss of partial 
self-tolerance to tyrosinase.35 We therefore test-
ed epistasis between HLA-A SNP rs12206499 and 
TYR SNP rs1393350 with logistic regression analy-
sis, using SNP genotypes from the genomewide 
association study and replication set 1, thereby 
detecting evidence of significant epistasis between 
HLA-A and TYR (P = 0.03).
Discussion
We identified 10 independent susceptibility loci 
for generalized vitiligo. In general, these associa-
tions were observed in both the subgroup of pa-
tients with vitiligo only and the subgroup with 
vitiligo and concomitant autoimmune diseases 
(Table 4 in the Supplementary Appendix). PTPN22 
(rs2476601) was the exception; the risk allele was 
significantly more prevalent among patients with 
generalized vitiligo and other autoimmune dis-
eases. In the MHC region, we detected two ma-
jor association signals, one in the class I gene 
region, between HLA-A and HCG9, and the other 
in the class II gene region, between HLA-DRB1 and 
HLA-DQA1 (Fig. 2). This finding is consistent with 
previous reports of an association of vitiligo with 
the HLA-A*02 allele16 and the HLA-DRB1*04 al-
lele.15 Indeed, the near-perfect linkage disequi-
librium between HLA-A*02 and the risk variant at 
rs12206499 suggests that HLA-A*02 may be the 
etiologic variant at this locus that confers suscep-
tibility to vitiligo.
Outside the MHC, we identified signals of an 
association with generalized vitiligo within or 
near the RERE, PTPN22, LPP, IL2RA, TYR, GZMB, 
UBASH3A, and C1QTNF6 genes. PTPN22, LPP, IL2RA, 
UBASH3A, and C1QTNF6 are also associated with 
genetic susceptibility to other autoimmune dis-
eases, several of which are epidemiologically as-
sociated with generalized vitiligo. These findings 
support the long-standing hypothesis that gen-
eralized vitiligo involves genetic susceptibility loci 
shared with other autoimmune diseases.3 Most of 
these genes encode immune-system proteins in-
volved in biologic pathways that probably influ-
ence the development of autoimmunity.
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In contrast, TYR encodes tyrosinase, which is 
not a component of the immune system. Rather, 
it is an enzyme of the melanocyte that catalyzes 
the rate-limiting steps of melanin biosynthesis.32 
It is also a major autoantigen in generalized vit-
iligo.1,2 Generalized vitiligo is thus genetically 
analogous to type 1 diabetes, in which variation 
in the INS gene, encoding insulin (an important 
autoantigen in diabetes), contributes to disease 
susceptibility. Vitiligo is associated with the ma-
jor alleles of SNPs in the TYR region, particularly 
rs1393350 (in the combined analysis, P = 1.60× 
10−18; odds ratio, 1.53) and the nearby nonsyn-
onymous (R402Q) SNP rs1126809 (Table 5 in the 
Supplementary Appendix), with which rs1393350 
is in tight linkage disequilibrium (Table 6 in the 
Supplementary Appendix). The minor alleles of 
both these SNPs are associated with susceptibil-
ity to malignant melanoma,36,37 suggesting that 
susceptibility to TYR-related generalized vitiligo 
and susceptibility to TYR-related malignant mel-
anoma are mediated by different or perhaps even 
inverse biologic mechanisms. The 402Q variant of 
the TYR protein (the variant associated with mela-
noma) is thermosensitive38 and at 37°C tends to 
be misfolded, aberrantly glycosylated, retained in 
the endoplasmic reticulum, and subject to pro-
teosomal degradation,39 resulting in steady-state 
402Q tyrosinase activity that is only 25% of that 
of the major 402R polypeptide (which is associ-
ated with susceptibility to generalized vitiligo).38 
Correct glycosylation of tyrosinase augments the 
generation of an MHC class I–restricted tyrosi-
nase epitope that is presented by HLA-A*0201,40 
the predominant HLA-A*02 allele, and indeed, we 
detected significant epistasis between HLA-A SNP 
rs12206499 and TYR SNP rs1393350 (P = 0.03).
Thus, 402R tyrosinase not only is expressed at 
higher levels than the 402Q variant but also may 
be more efficiently presented to the immune sys-
tem by HLA-A*02. It is therefore plausible that the 
402R variant makes a greater contribution than 
the 402Q variant to immune surveillance against 
neoplastic melanocytes and susceptibility to viti-
ligo. On the other hand, in persons carrying one 
or two copies of the 402Q variant, immune sur-
veillance may fail to detect neoplastic melanocytes, 
owing to the reduced expression, and thus the 
reduced immune presentation, of tyrosinase.
Generally, there is limited correspondence be-
tween the associations shown in the present study 
and genetic linkage and candidate-gene associa-
tion signals reported previously for generalized 
vitiligo,3 though a detailed analysis supported an 
association with NLRP1 in multiplex families and 
specific subgroups of patients (see the Supplemen-
tary Appendix). Moreover, none of the significant 
associations reported in this study correspond to 
the principal up-regulated or down-regulated tran-
scripts identified with the use of gene-expression 
profiling of melanocytes from patients with gen-
eralized vitiligo.41 Although the implicated loci 
that we have described here together account for 
only approximately 7.4% of the total genetic risk 
for generalized vitiligo, they provide insights into 
disease pathogenesis and implicate potential tar-
gets for therapeutic intervention.
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